These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16503937)

  • 21. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
    Epping MT; Bernards R
    Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
    Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
    Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitors as anti-neoplastic agents.
    Batty N; Malouf GG; Issa JP
    Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetics of melanoma tumorigenesis.
    Singh M; Lin J; Hocker TL; Tsao H
    Br J Dermatol; 2008 Jan; 158(1):15-21. PubMed ID: 18047516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
    Duenas-Gonzalez A; Candelaria M; Perez-Plascencia C; Perez-Cardenas E; de la Cruz-Hernandez E; Herrera LA
    Cancer Treat Rev; 2008 May; 34(3):206-22. PubMed ID: 18226465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of vorinostat: current applications and future perspectives for cancer therapy.
    Richon VM; Garcia-Vargas J; Hardwick JS
    Cancer Lett; 2009 Aug; 280(2):201-10. PubMed ID: 19181442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
    Garmpis N; Damaskos C; Garmpi A; Dimitroulis D; Spartalis E; Margonis GA; Schizas D; Deskou I; Doula C; Magkouti E; Andreatos N; Antoniou EA; Nonni A; Kontzoglou K; Mantas D
    Anticancer Res; 2017 Oct; 37(10):5355-5362. PubMed ID: 28982843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA.
    Mitra AP
    IDrugs; 2009 Jun; 12(6):339-41. PubMed ID: 19517310
    [No Abstract]   [Full Text] [Related]  

  • 31. Epigenetic mechanisms in glioblastoma multiforme.
    Nagarajan RP; Costello JF
    Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
    Vendetti FP; Rudin CM
    Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
    Ropero S; Fraga MF; Ballestar E; Hamelin R; Yamamoto H; Boix-Chornet M; Caballero R; Alaminos M; Setien F; Paz MF; Herranz M; Palacios J; Arango D; Orntoft TF; Aaltonen LA; Schwartz S; Esteller M
    Nat Genet; 2006 May; 38(5):566-9. PubMed ID: 16642021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.
    Wang Y; Fan PS; Kahaleh B
    Arthritis Rheum; 2006 Jul; 54(7):2271-9. PubMed ID: 16802366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HDAC inhibitors: clinical update and mechanism-based potential.
    Glaser KB
    Biochem Pharmacol; 2007 Sep; 74(5):659-71. PubMed ID: 17498667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibitors in multiple myeloma.
    Anderson KC
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S20-6. PubMed ID: 19393832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic regulation of airway inflammation.
    Adcock IM; Tsaprouni L; Bhavsar P; Ito K
    Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting aberrant chromatin structure in colorectal carcinomas.
    Konishi K; Issa JP
    Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases.
    Hölsken A; Eyüpoglu IY; Lueders M; Tränkle C; Dieckmann D; Buslei R; Hahnen E; Blümcke I; Siebzehnrübl FA
    Acta Neuropathol; 2006 Aug; 112(2):205-15. PubMed ID: 16773328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.